In hemodialysis patients with adynamic bone disease, femoral neck BMD increased nonsignificantly during teriparatide treatment compared with pretreatment change.
In plain wordsIn dialysis patients with low bone activity, femoral neck bone density increased nonsignificantly during teriparatide treatment compared with pretreatment change.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- No significant changeFemoral neck bone mineral density annual change
- Study
n = 9
- Comparator
- Before treatment
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- Dose not stated · 13-16 monthsAs given in this study (human).
Measurements
- Annual FN BMD change
- −5.4%
- before treatment
- Annual FN BMD change
- 2.7%
- during teriparatide
Source sentences
In the teriparatide group, FN and LS BMD increased, although not significantly, with an annual change of -5.4 and -2.6% before treatment to 2.7 and 4.9% during treatment, respectively.
3 context sentences(design, population, supporting numbers)
Depending on both the bone biopsy findings and parathyroid hormone levels, patients were assigned to treatment groups.
Eleven patients with osteitis fibrosa and iPTH >300 pg/ml received cinacalcet, 11 with osteitis fibrosa and iPTH <300 pg/ml received ibandronate, 9 with adynamic bone disease received teriparatide, and 7 with mild abnormalities received no treatment.
A third BMD measurement was done after an average treatment period of 13-16 months.